Daypro Alta Alternatives Compared
| Daypro Alta (oxaprozin) | Cimzia (certolizumab) | Adalimumab |
|
|---|
| Daypro Alta (oxaprozin) | Cimzia (certolizumab) | Adalimumab |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Osteoarthritis, Juvenile Rheumatoid Arthritis, Rheumatoid Arthritis. Daypro Alta may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Ankylosing Spondylitis, Crohn's Disease, Crohn's Disease - Active, Crohn's Disease - Maintenance, Non-Radiographic Axial Spondyloarthritis, Plaque Psoriasis, Polyarticular Juvenile... View more |
Prescription only
Adalimumab is a TNF-alfa inhibitor that may be used to treat a wide range of different inflammatory conditions, such as rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and... View more |
Related suggestions Rheumatoid Arthritis
|
|||||||
| More about (oxaprozin) | More about Cimzia (certolizumab) | More about Adalimumab | ||||||||
| Ratings & Reviews | ||||||||||
|
Be the first to share your experience with this drug. |
Cimzia has an average rating of 6.7 out of 10 from a total of 90 ratings on Drugs.com. 51% of reviewers reported a positive effect, while 21% reported a negative effect. |
Adalimumab has an average rating of 6.4 out of 10 from a total of 723 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 31% reported a negative effect. |
||||||||
| Drug Class | ||||||||||
| Side Effects | ||||||||||
| Generic Availability | ||||||||||
| Lower cost generic approved |
N/A |
Lower cost generic |
||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Adalimumab prices |
||||||||
| Dosage Forms Available | ||||||||||
|
N/A |
|
|
||||||||
| Brand Names | ||||||||||
| Other oxaprozin brands include: Coxanto, Daypro |
N/A |
Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Humira, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry View more | ||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
|
50 hours |
336 hours |
480 hours |
||||||||
| CSA Schedule ** View glossary of terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 362 drugs are known to interact with Daypro Alta:
|
A total of 427 drugs are known to interact with Cimzia:
|
A total of 540 drugs are known to interact with Adalimumab:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
N/A |
April 22, 2008 |
N/A |
||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient resources | ||||||||||
|
N/A |
||||||||||
| Professional Resources | ||||||||||
|
N/A |
||||||||||
| Related Treatment Guide | ||||||||||
|
||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.